BeiGene and CSPC Pharmaceutical Collaborate to Develop SYH2039 for Solid Tumors
Shots:
- BeiGene has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology to develop SYH2039 for solid tumors
- BeiGene secures exclusive global rights to develop, manufacture & commercialize SYH2039. CSPC will receive $150M upfront, development & commercial milestones as well as tiered royalties
- SYH2039 targets MTAP-deleted solid tumors, present in ~15% of cancers like glioblastoma, pancreatic & NSCLC. BeiGene plans to explore its potential, including combinations with BGB-58067, a next-gen PRMT5 inhibitor entering trials by YE’24 with improved safety and best-in-class potential
Ref: Businesswire | Image: BeiGene and CSPC Pharmaceutical
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
